Indefinite Delivery Contract 75N91024D00005
Award Date
1/25/24
Last Date to Order
1/24/29
Federal Agency
National Cancer Institute
Awardee
University Of Oklahoma
Ultimate Awardee
University Of Oklahoma
Federal Contract Vehicle
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Employment Eligibility Verification
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This is a multiple award Indefinite Delivery Contract (IDC) issued by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services. The contract has a ceiling value of $9,950,000 and was awarded to the University of Oklahoma (OU) to provide preclinical research and development services related to cancer prevention and treatment. The task orders issued under this IDC cover a range of preclinical oncology research activities, including the evaluation of...
The federal contract IDV award is an Indefinite Delivery Contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of Oklahoma (OU). The contract vehicle is titled "Preclinical Agent Development Assays 2012-2016" and has a ceiling value of $9,900,000. Under this IDIQ contract, OU has been issued multiple delivery orders totaling over $4.8 million to conduct preclinical research and development...
This indefinite delivery contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health within the Department of Health and Human Services, to IIT Research Institute (IITRI), a non-profit contract research organization. The $74,995,000 multiple-award contract, titled the "PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarkers," supports preclinical efficacy and biomarker evaluation, manufacturing, and...
This indefinite delivery contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS). The contract, valued at up to $74,995,000, is a multiple award with Advanced Bioscience Laboratories, Inc. (ABL) as the prime contractor. The contract supports the PREVENT Cancer Preclinical Drug Development Program, with the objective of cGMP production of vaccines and biologicals for cancer prevention. Key...
This indefinite delivery contract was awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to the University of Alabama at Birmingham (UAB) to support the agency's Preclinical Prevent Cancer Program. The program focuses on evaluating the preclinical efficacy and identifying intermediate biomarkers for potential cancer prevention agents prior to clinical trials. Under this $29.8 million multiple-award IDC, UAB has been issued multiple...
The contract IDV award is for the PREVENT Cancer Preclinical Drug Development Program, a multiple-award IDIQ contract administered by the National Cancer Institute (NCI). The program encompasses three main technical areas: (1) evaluation of the efficacy and pharmacodynamic/efficacy biomarkers for potential cancer preventive agents, (2) preclinical product development, analytical testing, process development, and cGMP manufacturing support for cancer preventive vaccines, and (3) pharmacological...
The National Cancer Institute (NCI) awarded a $74,995,000 multiple-award indefinite delivery/indefinite quantity (IDIQ) contract called the PREVENT Preclinical Drug Development Program to support preclinical pharmacology, toxicology, and product development services for cancer therapy candidates. The prime contractor, IIT Research Institute (IITRI), is a non-profit division of the Illinois Institute of Technology that specializes in these preclinical services for federal agencies. Under this...
This indefinite delivery contract (IDC) was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to The University of Texas MD Anderson Cancer Center (MD Anderson). The $149,995,000 multiple-award IDIQ contract supports the NCI's "PREVENT Cancer Preclinical Drug Development Program" and covers preclinical efficacy and biomarker evaluation of potential cancer preventive agents. Under this IDC, MD Anderson has been awarded a $1,144,300...
The contract awarded to Curia Bio Inc. is an Indefinite Delivery Contract (IDC) with the National Cancer Institute (NCI), a civilian agency, to support the PREVENT Cancer Preclinical Drug Development Program. The single-award IDC has a ceiling value of $149,995,000.00 and a period of performance through January 24, 2029. The purpose of this contract is to provide a structured approach to drug and vaccine development for cancer prevention, spanning discovery through clinical trials. The...
The University of Texas MD Anderson Cancer Center was awarded an indefinite delivery, indefinite quantity (IDIQ) contract from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to support the PREVENT Preclinical Drug Development Program. This multiple award IDIQ has a $74,995,000 ceiling and a 5-year base period with a 5-year option. It covers three pools of services: preclinical efficacy and biomarker evaluation, preclinical GMP product development and...
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Completion Date (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
Delivery Order 75N91024D00005-75N91024F00002 | University Of Oklahoma | $1.9m | 6/17/24 | 12/16/25 | 8/7/24 |